ArticleBMC ophthalmology2025
Comparative study of the retinal structure and visual acuity in 7-12-year-old children between children with a history of treatment of retinopathy of prematurity and regressed retinopathy of prematurity: multicenter review of J-CREST.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quality of life after cultured corneal endothelial cell transplant in patients with bullous keratopathy.Japanese journal of ophthalmology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrevious studies have reported the efficacy of photocoagulation (PC) therapy for treating retinopathy of prematurity (ROP); however, its long-term effects on visual function and retinal structure remain unclear. This study compared the visual function and retinal structure of school-aged children (7–12 years) with ROP who underwent PC therapy with those of children with untreated ROP.
methodsSeventy-eight eyes of 78 patients diagnosed with ROP who were followed up until school age were evaluated. Fifty-one eyes that underwent PC therapy and 27 eyes with spontaneously regressed ROP were included in the PC-treated and untreated groups, respectively. One eye of each patient was included in the analysis at random.
resultsThe mean best-corrected visual acuity (BCVA) in the PC-treated and untreated groups was 0.05 ± 0.19 and 0.04 ± 0.35 logarithm of the minimum angle of resolution (logMAR) units and no significant differences were observed (p = 0.896, t-test). The mean spherical equivalent in the PC-treated and untreated groups was − 4.2 ± 4.7 D and − 0.8 ± 2.5 D (p < 0.001). PC-treated eyes were treated at ROP zone II in 42/51 eyes, ROP stage 3 in 41/51 eyes and showed plus disease in 31/51 eyes. Untreated eyes were regressed from ROP zone II in 22/27 eyes, ROP stage3 in 8/27eyes, and showed plus disease in 3/27eyes. The eyes in the PC-treated group were more myopic than those in the untreated group; further, they exhibited a unique foveal morphology with thicker foveal thickness (274.2 ± 29.9 μm in the PC-treated and 239.9 ± 25.0 μm in the untreated groups p < 0.001), inner retinal layer retention (23.6 ± 12.5 μm in the PC-treated and 14.1 ± 7.1 μm in the untreated groups p = 0.004) and a thicker outer nuclear layer (130.3 ± 20.0 μm in the PC-treated and 110.8 ± 20.6 μm in the untreated groups p < 0.001). No significant differences were observed in the outer retinal, inner segment (43.7 ± 4.9 μm in the PC-treated and 45.2 ± 5.0 μm in the untreated groups p = 0.231), or outer segment (45.0 ± 4.6 μm in the PC-treated and 43.8 ± 4.8 μm in the untreated groups p = 0.238) layers’ thickness.
conclusionThe findings of the present study suggest that school-aged children who underwent PC therapy for ROP had good visual acuity, however the inner retinal structure remained immature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.